ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Jun 2, 2017
Dollar General: 27 Consecutive Years and Counting
The dollar store industry is one that often flies under the radar of many investors that are looking for more glamorous ideas. However, the often-counter recessionary trends of their businesses coupled with unit proliferation makes them worthy of consideration, in our view. We like Dollar General the most.
May 31, 2017
Nevro: An Exciting But Risky Medtech Idea in the Early Stages of Its Growth
Image Source: Nevro. Innovation continues to thrive in the medical field. The rapid aging of the industrialized world’s population bodes well for rising demand. Let’s look at a promising med tech idea, which we believe offers explosive growth in the field of Neuromodulation. It's a risky one though.
May 29, 2017
Dividend Increases/Decreases for the Week Ending May 26
Let's take a look at companies that raised/lowered their dividends this week.
May 26, 2017
Alexion’s Executive Departures and an Update from Regeneron Pharma
Image shown above: Performance of Regeneron since the summer of 2013.An executive scandal continues to mar the performance of Alexion Pharmaceuticals. The CFO has resigned his position effective the end of August, but there is more to this story. Let’s also talk Regeneron.
May 25, 2017
Alerts – Spring Cleaning in the Newsletter Portfolios
We’re making a number of changes to the newsletter portfolios.
May 25, 2017
Subscribe to Valuentum by Credit or Debit Card
View this article to subscribe to Valuentum by credit card.
May 24, 2017
Changing Millennial Preferences and the Death of the Blue Box?
Image Source: samantha celera. The widely-held thesis that the ultra-rich care more about status than function may be waning as convergence between the two ensue. Let's talk Tiffany and the ultra-luxury space.
May 24, 2017
Pipeline Woes Continue to Plague Amgen
Image Source: kibbles_bits. The commercial viability of a biotech outfit’s pipeline can often determine the future path of the share price. Irrespective of the past performance, if a company cannot innovate, it will witness its competitive position erode, leading to an inevitable decline in revenue. The latest setback from the clinical labs continues to support a bearish stance on Amgen.
May 23, 2017
Cracker Barrel Hits the Trifecta!
Image Source: Mike Mozart. Cracker Barrel increased its full-year earnings guidance, raised its regular dividend, and issued a special payout. The market was pleased.
May 22, 2017
Investing Versus Speculating: Ford, GM, Tesla
Ford is making some changes at the top, but we still like General Motors. Tesla’s stock remains “uninvestable,” in our view.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.